GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (STU:PH4) » Definitions » EV-to-FCF

CStone Pharmaceuticals (STU:PH4) EV-to-FCF : -2.95 (As of May. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CStone Pharmaceuticals's Enterprise Value is €78.30 Mil. CStone Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was €-26.55 Mil. Therefore, CStone Pharmaceuticals's EV-to-FCF for today is -2.95.

The historical rank and industry rank for CStone Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:PH4' s EV-to-FCF Range Over the Past 10 Years
Min: -21.42   Med: -2.61   Max: -0.49
Current: -3.14

During the past 8 years, the highest EV-to-FCF of CStone Pharmaceuticals was -0.49. The lowest was -21.42. And the median was -2.61.

STU:PH4's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs STU:PH4: -3.14

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), CStone Pharmaceuticals's stock price is €0.125. CStone Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.084. Therefore, CStone Pharmaceuticals's PE Ratio for today is At Loss.


CStone Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for CStone Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals EV-to-FCF Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -5.84 -11.55 -3.96 -5.91 -3.03

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.96 - -5.91 - -3.03

Competitive Comparison of CStone Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, CStone Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CStone Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's EV-to-FCF falls into.



CStone Pharmaceuticals EV-to-FCF Calculation

CStone Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=78.299/-26.548
=-2.95

CStone Pharmaceuticals's current Enterprise Value is €78.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CStone Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was €-26.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CStone Pharmaceuticals  (STU:PH4) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CStone Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.125/-0.084
=At Loss

CStone Pharmaceuticals's share price for today is €0.125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CStone Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.084.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CStone Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CStone Pharmaceuticals (STU:PH4) Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (STU:PH4) Headlines

No Headlines